Columbia University Glomerular Disease 2026 – 15th Annual Update (Videos)

Advanced Clinical Update in Glomerular Disease Diagnosis & Management

The Columbia University Glomerular Disease 2026 – 15th Annual Update provides a focused, evidence-based review of the latest advances in glomerular disease diagnosis, therapeutics, and clinical management.

Presented by the renowned Glomerular Kidney Disease Center, this ACCME-accredited program delivers practical updates on evolving treatment strategies, emerging targeted therapies, and real-world approaches to managing complex glomerular disorders.

The course emphasizes modern nephrology practice with expert discussions on:

• IgA nephropathy
• C3 glomerulopathy (C3G)
• ANCA-associated vasculitis
• Targeted immunologic therapies
• SGLT2 inhibitors in glomerular disease
• Treatment-related adverse event management
• Case-based clinical decision making

Designed for practicing clinicians and nephrology specialists, the program integrates current guidelines, clinical trial evidence, and patient-centered management strategies to improve outcomes in glomerular kidney disease.

---

📦 Product Details

• 🎥 Format: Video Lectures
• 🌐 Access: On-demand
• 🧠 Level: Advanced Nephrology & Glomerular Disease Update
• 🏛️ Presented by: Columbia University Glomerular Kidney Disease Center

---

🩺 Program Overview

Glomerular diseases continue to evolve rapidly with the emergence of:

• Precision immunologic therapies
• Complement-targeted treatments
• Novel biologic agents
• Updated KDIGO recommendations
• Expanded use of SGLT2 inhibitors
• Personalized treatment strategies

This one-day intensive course provides clinicians with practical guidance for diagnosing and managing both common and complex glomerular disorders using evidence-based approaches.

The curriculum combines:
✔️ Current treatment guidelines
✔️ Clinical trial updates
✔️ Real-world management strategies
✔️ Challenging case discussions
✔️ Emerging therapeutic developments

to help nephrology professionals integrate modern glomerular disease care into daily clinical practice.

---

🎯 Learning Objectives

After completing this course, participants will be able to:

• Identify current treatment guidelines for glomerular diseases
• Explore targeted therapies for C3 glomerulopathy, IgA nephropathy, and ANCA vasculitis
• Assess the role of SGLT2 inhibitors in non-diabetic glomerular disease
• Discuss monitoring and management of treatment-related adverse events
• Apply evidence-based approaches through case studies and real-world clinical scenarios

---

🧬 IgA Nephropathy & Emerging Therapies

The course provides updated guidance on modern management of IgA nephropathy.

Topics include:

• Risk stratification
• Proteinuria reduction strategies
• Immunosuppressive therapy
• Complement-targeted therapies
• Novel disease-modifying agents
• KDIGO guideline updates

Faculty discuss evolving approaches designed to slow disease progression and improve long-term renal outcomes.

---

⚡ C3 Glomerulopathy (C3G)

Specialized sessions review:

• Complement pathway dysregulation
• Diagnostic evaluation of C3G
• Emerging complement inhibitors
• Precision medicine approaches
• Monitoring treatment response

Experts highlight the expanding role of targeted therapies in managing complement-mediated kidney diseases.

---

🛡️ ANCA-Associated Vasculitis

The program also explores advances in:

• ANCA vasculitis diagnosis
• Induction and maintenance therapy
• Rituximab and biologic therapies
• Steroid-sparing treatment strategies
• Relapse prevention
• Monitoring treatment toxicity

Sessions emphasize individualized treatment selection and long-term disease management.

---

💊 SGLT2 Inhibitors in Glomerular Disease

A major focus of the course is the expanding role of SGLT2 inhibitors beyond diabetic kidney disease.

Topics include:

• Renoprotective mechanisms
• Proteinuria reduction
• CKD progression prevention
• Non-diabetic glomerular disease applications
• Safety considerations and monitoring

Faculty review current evidence supporting the integration of SGLT2 inhibitors into modern nephrology practice.

---

⚠️ Adverse Event Monitoring & Safety

The course provides practical guidance for:

• Monitoring immunosuppressive therapy
• Managing treatment-related complications
• Infection risk reduction
• Long-term medication safety
• Balancing efficacy with toxicity

These sessions help clinicians optimize therapeutic outcomes while minimizing treatment-related risks.

---

🧠 Case-Based Learning & Clinical Application

Real-world case discussions form a core component of the program.

Interactive clinical scenarios help participants:
✔️ Apply guideline-based management
✔️ Interpret biopsy and laboratory findings
✔️ Navigate difficult treatment decisions
✔️ Individualize therapy for complex patients
✔️ Improve long-term disease monitoring strategies

The case-based format strengthens practical clinical reasoning in glomerular disease care.

---

💡 Key Features

✔️ Advanced glomerular disease update
✔️ Evidence-based nephrology education
✔️ Current KDIGO and treatment guideline review
✔️ Emerging targeted therapies and biologics
✔️ Focus on C3G, IgA nephropathy, and ANCA vasculitis
✔️ SGLT2 inhibitor integration into nephrology practice
✔️ Practical case-based clinical discussions
✔️ ACCME-accredited educational program

---

🚀 Why This Course Stands Out

The Columbia University Glomerular Disease 2026 – 15th Annual Update delivers a focused and clinically relevant review of modern glomerular disease management from one of the leading kidney disease centers.

The course combines:

• Cutting-edge nephrology updates
• Precision medicine strategies
• Targeted immunologic therapies
• Practical clinical guidance
• Real-world patient management

to help clinicians stay current with rapidly evolving approaches in glomerular disease diagnosis and treatment.

This program is an outstanding educational resource for nephrology professionals seeking advanced updates in glomerular disease care for 2026.